Blood-thinning drugs that doctors often prescribe interchangeably after procedures to reopen narrowed heart arteries don’t work equally well in patients with diabetes, a study from India found.
All 1,800 study participants had Type 1 or Type 2 diabetes, and all had undergone minimally invasive interventions to clear a clogged coronary artery and prop it open using a drug-coated stent to help reduce the risk of reclogging.
Afterward, they received aspirin plus either AstraZeneca's Brilinta (ticagrelor) or Effient (prasugrel), sold by Eli Lilly and Daiichi Sankyo, from a class of drugs known as P2Y12 inhibitors that are prescribed to prevent the formation of blood clots.
The combined rate of heart attack, stroke, bleeding complications or death was 16.6% in the ticagrelor group and 14.2% in the prasugrel group, researchers reported at the recent American Heart Association Scientific Sessions in New Orleans.
Patterns were similar when rates of non-fatal heart attack, major bleeding, and death were analyzed separately.
“For individuals with Type 1 or Type 2 diabetes and complex coronary disease, there may be an advantage to treatment with prasugrel over ticagrelor,” study leader Dr. Sripal Bangalore of the NYU Grossman School of Medicine said in a statement.
“We were surprised by the results because we hypothesized that ticagrelor should be as good or perhaps even better than prasugrel," he said. "It’s important to choose the right medicine, and at least from our data, we cannot say that ticagrelor and prasugrel are interchangeable.”